Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Open-Label, Non-controlled Study to Evaluate the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (rpFVIII, TAK-672), in the Treatment of Serious Bleeding Episode in Japanese Subjects With Acquired Hemophilia A (AHA)

NCT04580407 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04580407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04580407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Open-Label, Non-controlled Study to Evaluate the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (rpFVIII, TAK-672), in the Treatment of Serious Bleeding Episode in Japanese Subjects With Acquired Hemophilia A (AHA)
Lead sponsor
Takeda
Phase
Phase 2/3
Overall status
Completed
Start date
April 9, 2021
Completion date
November 29, 2022
Enrollment
5 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acquired hemophilia a